A team from the SWOG Cancer Research Network that analyzed data on more than 20,000 patients from more than 200 clinical trials reports found that compared to men, women have a higher risk of severe adverse events from targeted therapy and immunotherapy. Past research has also shown that women tend to have more adverse events from chemotherapy.
Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral reproduction.
